Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

BayCare Health System

Status: Enrolling

Conditions: Acute Kidney Injury

Study type: Observational

Funder types: Other

Identifiers

NCT07197957

Cystatin & Early AKI Detection

Details and patient eligibility

About

To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).

Full description

The primary objective of this study is to evaluate the clinical utility of Cystatin C in early detection of contrast-induced AKI.

To evaluate the effect of patient characteristics in the Cystatin C based GFR estimation in comparison to Cr based estimation.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects ages 18 years and above
• Inpatients with CKD (Figure 1)
• Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media.
• Pre and post contrast available
• All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.

Exclusion criteria

• Preexisting dialysis
• Patients under the age of 18 years
• Pregnancy
• Incarcerated individuals
• Patients with impaired cognition and unable to follow consent procedures
• Recent exposure to CM (within 2 days before/after procedure)
• Cardiac shock
• Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim